Mubadala Bio and Baynouna Gene Solutions expand UAE diagnostics reach

READY
Read by Emma, the Simply Abu Dhabi narrator.
A regional distribution agreement connects locally designed molecular diagnostic kits to healthcare providers across the UAE and beyond, anchoring innovation in the place where it is made.
The architecture of a resilient healthcare system depends less on grand ambitions than on the practical work of connecting innovation to the people who need it. That principle animated a partnership signed this week at the 46th ICMM World Congress of Military Medicine in Abu Dhabi: Mubadala Bio, through its company Al Ittihad Drug Store, has entered a regional distribution agreement with Baynouna Gene Solutions to expand access to advanced molecular diagnostic kits designed and manufactured within the UAE.
The agreement unites two distinct strengths. Baynouna Gene Solutions brings expertise in molecular diagnostics design and production, including a pioneering achievement: it was the first operation in the Middle East to manufacture commercial primers using enzymatic DNA synthesis. Al Ittihad Drug Store contributes an established distribution network across the UAE and the region, the infrastructure required to move a product from laboratory to clinic. The pairing reflects a deliberate strategy to build capability across the entire life sciences value chain, from design through manufacturing to the final point of care.
Dr. Bakheet Al Katheeri, Chief Executive of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, positioned the work within a broader vision. “Developing strong local capabilities across the life sciences value chain is essential to building a resilient healthcare ecosystem,” he observed. “This agreement supports local innovation while helping expand access to advanced diagnostic solutions across the UAE.”
The timing aligns with Mubadala Bio’s broader platform consolidation. As we reported in October, the company has been forging partnerships to establish advanced pharmaceutical capabilities in Abu Dhabi. This diagnostics agreement extends that logic: local design and manufacture reduce dependence on external supply chains whilst positioning the UAE as a knowledge hub in molecular biology and diagnostics.
Prof. Habiba Alsafar, Deputy Chair of Baynouna Gene Solutions, articulated the scientific ambition beneath the commercial arrangement. “Pioneering commercial DNA synthesis in the region gives us a platform to support research in synthetic and molecular biology and to turn discoveries made here into products that meet real needs.” That formulation captures something essential: the movement from research capability to market application, from theoretical work to tangible healthcare solutions.
Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, described the distribution partnership as a step in connecting “locally developed solutions with the distribution capabilities required to reach healthcare providers across the UAE and the region.” Dr. Omar Najim, Chief Executive of Baynouna Gene Solutions, echoed the point: “Through IDS, we can serve more customers across the UAE and the region while continuing to support industry and research teams.”
Al Ittihad Drug Store operates within Mubadala Bio’s Pharma Logistics vertical, a division handling the distribution and market access of medicines, medical devices and healthcare products across the UAE. The diagnostics agreement extends this infrastructure to support not only pharmaceutical goods but the advanced diagnostic tools upon which modern clinical decision-making rests.
What it means for Abu Dhabi
The partnership advances the UAE’s stated vision to establish itself as a regional hub for life sciences innovation and advanced manufacturing. By connecting Baynouna’s design and production expertise with Al Ittihad’s distribution reach, the agreement strengthens local supply chains and reduces reliance on imported diagnostic solutions, a strategic imperative for any healthcare system seeking resilience and self-sufficiency.
For Abu Dhabi specifically, the work reinforces the emirate’s emerging position as a centre of life sciences research and manufacturing. Mubadala Bio’s platform now spans research, manufacturing, logistics and commercialisation, each function anchored locally. The Baynouna partnership demonstrates how these functions can interact to create competitive advantage: discoveries made in UAE laboratories can move directly into manufacturing facilities and from there into the hands of clinicians and researchers, without crossing international borders or navigating external supply constraints.
On Simply Luxury: Mubadala